Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 185

1.

Structural diversity of xylans in the cell walls of monocots.

Peña MJ, Kulkarni AR, Backe J, Boyd M, O'Neill MA, York WS.

Planta. 2016 Apr 22. [Epub ahead of print]

PMID:
27105886
2.

Ruxolitinib versus best available therapy in patients with Polycythemia Vera: 80 Week follow up from the RESPONSE trial.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ.

Haematologica. 2016 Apr 21. pii: haematol.2016.143644. [Epub ahead of print]

3.

Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease.

Montgomery M, van Santen MM, Biemond BJ, Diamond RH, Pals ST.

Gastroenterol Hepatol (N Y). 2015 Mar;11(3):160-3.

4.

Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions - an Industry Perspective.

Bohnert T, Patel A, Templeton I, Chen Y, Lu C, Lai G, Leung L, Tse S, Einolf HJ, Wang YH, Sinz M, Stearns R, Walsky R, Geng W, Sudsakorn S, He L, Wahlstrom J, Keirns J, Narayanan R, Lang D, Yang X.

Drug Metab Dispos. 2016 Apr 6. pii: dmd.115.069096. [Epub ahead of print]

PMID:
27052879
5.

The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.

Salem I, Alsalahi M, Chervoneva I, Aburto LD, Addya S, Ott GR, Ruggeri BA, Cristofanilli M, Fernandez SV.

Breast Cancer Res. 2016 Mar 24;18(1):37. doi: 10.1186/s13058-016-0694-4.

6.

Oxidative Stress in Atopic Dermatitis.

Ji H, Li XK.

Oxid Med Cell Longev. 2016;2016:2721469. doi: 10.1155/2016/2721469. Epub 2016 Feb 23. Review.

7.

Potential Under-Prediction of Warfarin Drug Interaction from Conventional Interaction Studies & Risk Mitigation: A Case Study with Epacadostat, an IDO1 Inhibitor.

Shi JG, Chen X, Punwani NG, Williams WV, Yeleswaram S.

J Clin Pharmacol. 2016 Mar 16. doi: 10.1002/jcph.737. [Epub ahead of print]

PMID:
26990117
8.

Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities.

Tabbò F, Pizzi M, Kyriakides PW, Ruggeri B, Inghirami G.

Oncotarget. 2016 Mar 2. doi: 10.18632/oncotarget.7853. [Epub ahead of print]

9.

Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.

Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D, DeMarini DJ, Gardner O, Crist W, Patel K.

Cancer Chemother Pharmacol. 2016 Apr;77(4):807-17. doi: 10.1007/s00280-016-2993-y. Epub 2016 Mar 3.

PMID:
26940938
10.

Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.

Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO.

BMC Cancer. 2016 Feb 27;16(1):167. doi: 10.1186/s12885-016-2208-2.

11.

Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development.

Cheng Y, El-Kattan A, Zhang Y, Ray AS, Lai Y.

Chem Res Toxicol. 2016 Apr 18;29(4):545-63. doi: 10.1021/acs.chemrestox.5b00511. Epub 2016 Mar 8.

PMID:
26889774
12.

Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.

Ahlberg E, Amberg A, Beilke LD, Bower D, Cross KP, Custer L, Ford KA, Van Gompel J, Harvey J, Honma M, Jolly R, Joossens E, Kemper RA, Kenyon M, Kruhlak N, Kuhnke L, Leavitt P, Naven R, Neilan C, Quigley DP, Shuey D, Spirkl HP, Stavitskaya L, Teasdale A, White A, Wichard J, Zwickl C, Myatt GJ.

Regul Toxicol Pharmacol. 2016 Feb 13;77:1-12. doi: 10.1016/j.yrtph.2016.02.003. [Epub ahead of print]

PMID:
26879463
13.

A Multi-Institution Phase 1 Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS.

Clin Cancer Res. 2016 Feb 8. pii: clincanres.2781.2015. [Epub ahead of print]

PMID:
26858309
14.

Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review.

Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ.

Exp Hematol Oncol. 2016 Feb 1;5:3. doi: 10.1186/s40164-016-0031-8. eCollection 2015.

15.

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT.

J Clin Oncol. 2016 Mar 10;34(8):871-8. doi: 10.1200/JCO.2015.62.9345. Epub 2016 Jan 25.

PMID:
26811525
16.

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.

Bissonnette R, Luchi M, Fidelus-Gort R, Jackson S, Zhang H, Flores R, Newton R, Scherle P, Yeleswaram S, Chen X, Menter A.

J Dermatolog Treat. 2016 Jan 14:1-7. [Epub ahead of print]

PMID:
26769332
17.

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.

Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Zhen H, Jones MM, Parasuraman S, Li J, Côté I, Habr D, Vannucchi AM.

Eur J Haematol. 2015 Nov 26. doi: 10.1111/ejh.12707. [Epub ahead of print]

PMID:
26608702
18.

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.

Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J.

Leukemia. 2015 Nov 3. doi: 10.1038/leu.2015.310. [Epub ahead of print] No abstract available.

PMID:
26526986
19.

Ethynylphenyl carbonates and carbamates as dual-action acetylcholinesterase inhibitors and anti-inflammatory agents.

Saxena J, Meloni D, Huang MT, Heck DE, Laskin JD, Heindel ND, Young SC.

Bioorg Med Chem Lett. 2015 Dec 1;25(23):5609-12. doi: 10.1016/j.bmcl.2015.10.039. Epub 2015 Oct 23.

PMID:
26510670
20.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S.

J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.

PMID:
26392102
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk